BioLineRx Ltd.

BioLineRx Ltd.verified

BLRX

Price:

$0.2307

Market Cap:

$24.43M

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in...[Read more]

Industry

Biotechnology

IPO Date

2011-07-27

Stock Exchange

NASDAQ

Ticker

BLRX

The Enterprise Value as of December 2024 (TTM) for BioLineRx Ltd. (BLRX) is 45.21M

According to BioLineRx Ltd.’s latest financial reports and current stock price. The company's current Enterprise Value is 45.21M. This represents a change of -37.86% compared to the average of 72.75M of the last 4 quarters.

BioLineRx Ltd. (BLRX) Historical Enterprise Value (quarterly & annually)

How has BLRX Enterprise Value performed in the past?

The mean historical Enterprise Value of BioLineRx Ltd. over the last ten years is 59.94M. The current 45.21M Enterprise Value has changed 7.44% with respect to the historical average. Over the past ten years (40 quarters), BLRX's Enterprise Value was at its highest in in the June 2015 quarter at 129.79M. The Enterprise Value was at its lowest in in the September 2024 quarter at 20.78M.

Quarterly (TTM)
Annual

Average

59.94M

Median

51.19M

Minimum

27.92M

Maximum

111.50M

BioLineRx Ltd. (BLRX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of BioLineRx Ltd. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 207.45%

Maximum Annual Enterprise Value = 111.50M

Minimum Annual Increase = -56.74%

Minimum Annual Enterprise Value = 27.92M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2023111.50M207.45%
202236.27M-56.74%
202183.83M145.22%
202034.18M22.41%
201927.92M-47.01%
201852.70M-43.46%
201793.22M87.63%
201649.68M-20.34%
201562.37M30.68%
201447.73M-12.70%

BioLineRx Ltd. (BLRX) Average Enterprise Value

How has BLRX Enterprise Value performed in the past?

The current Enterprise Value of BioLineRx Ltd. (BLRX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

77.20M

5-year avg

58.74M

10-year avg

59.94M

BioLineRx Ltd. (BLRX) Enterprise Value vs. Peers

How is BLRX’s Enterprise Value compared to its peers?

BioLineRx Ltd.’s Enterprise Value is less than Ardelyx, Inc. (1.17B), less than Lexicon Pharmaceuticals, Inc. (335.20M), less than Seres Therapeutics, Inc. (192.05M), less than ImmunityBio, Inc. (2.54B), less than X4 Pharmaceuticals, Inc. (83.07M), less than Mereo BioPharma Group plc (503.18M), less than Inozyme Pharma, Inc. (209.16M), less than Terns Pharmaceuticals, Inc. (219.14M), less than Leap Therapeutics, Inc. (48.29M), less than Verrica Pharmaceuticals Inc. (86.67M), less than Verona Pharma plc (3.48B), greater than Galera Therapeutics, Inc. (-6817795.00), less than Arcutis Biotherapeutics, Inc. (1.82B), less than Protalix BioTherapeutics, Inc. (107.55M), greater than Cidara Therapeutics, Inc. (39.90M), less than Fortress Biotech, Inc. (62.09M), greater than Mustang Bio, Inc. (5.51M), greater than Achilles Therapeutics plc (-35577954.00), greater than Aptose Biosciences Inc. (24.24M), less than Fortress Biotech, Inc. (62.09M),

Build a custom stock screener for BioLineRx Ltd. (BLRX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BioLineRx Ltd. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

BioLineRx Ltd. (BLRX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like BioLineRx Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is BioLineRx Ltd.'s Enterprise Value?

What is the highest Enterprise Value for BioLineRx Ltd. (BLRX)?

What is the 3-year average Enterprise Value for BioLineRx Ltd. (BLRX)?

What is the 5-year average Enterprise Value for BioLineRx Ltd. (BLRX)?

How does the current Enterprise Value for BioLineRx Ltd. (BLRX) compare to its historical average?